MAGEA3 and neoplasm: In another study with lymphodepleted patients, researchers noted a concordance between tumor regression and a persistence of transduced T cells using autologous anti-MAGE-A3 112–120/HLA-A*0201 TCR (KVAELVHFL) engineered T cells (NCT01273181).